Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

Standard

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers. / Melling, Nathaniel; Bachmann, Kai; Hofmann, Bianca; El Gammal, Alexander Tarek; Reeh, Matthias; Mann, Oliver; Moebius, Christoph; Blessmann, Marco; Izbicki, Jakob Robert; Grupp, Katharina.

in: J CANCER RES CLIN, Jahrgang 145, Nr. 4, 04.2019, S. 873-879.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{9005d35828a745268429f8e22e919f3f,
title = "Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers",
abstract = "INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.",
keywords = "Adult, Aged, Aged, 80 and over, Biomarkers, Tumor/biosynthesis, Carcinoma, Non-Small-Cell Lung/metabolism, Female, Humans, Immunohistochemistry, Lung Neoplasms/metabolism, Male, Middle Aged, Neoplasm Staging, Prevalence, RNA-Binding Proteins/biosynthesis, Tissue Array Analysis",
author = "Nathaniel Melling and Kai Bachmann and Bianca Hofmann and {El Gammal}, {Alexander Tarek} and Matthias Reeh and Oliver Mann and Christoph Moebius and Marco Blessmann and Izbicki, {Jakob Robert} and Katharina Grupp",
year = "2019",
month = apr,
doi = "10.1007/s00432-019-02850-1",
language = "English",
volume = "145",
pages = "873--879",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

AU - Melling, Nathaniel

AU - Bachmann, Kai

AU - Hofmann, Bianca

AU - El Gammal, Alexander Tarek

AU - Reeh, Matthias

AU - Mann, Oliver

AU - Moebius, Christoph

AU - Blessmann, Marco

AU - Izbicki, Jakob Robert

AU - Grupp, Katharina

PY - 2019/4

Y1 - 2019/4

N2 - INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.

AB - INTRODUCTION: Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.MATERIALS AND METHODS: This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.RESULTS: While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers, Tumor/biosynthesis

KW - Carcinoma, Non-Small-Cell Lung/metabolism

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Lung Neoplasms/metabolism

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Prevalence

KW - RNA-Binding Proteins/biosynthesis

KW - Tissue Array Analysis

U2 - 10.1007/s00432-019-02850-1

DO - 10.1007/s00432-019-02850-1

M3 - SCORING: Journal articles

C2 - 30758670

VL - 145

SP - 873

EP - 879

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 4

ER -